The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) and Empagliflozin in Patients With Chronic Kidney Disease (EMPA-KIDNEY) trials form the cornerstone of SGLT2 inhibitor approvals [2, 3]. Here, SLC5A2 is linked to chronic kidney disease.